Jeffrey Marrazzo

Co-founder and Chief Executive OfficerSpark Therapeutics

Mr. Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark’s board of directors. Under his leadership, Spark has received regulatory approval for the first gene therapy for a genetic disease approved in both the U.S. and EU, launched the first gene therapy for a genetic disease in the U.S., and established human proof-of-concept of Spark’s gene therapy platform in both the retina and liver. In the six years since founding Spark, Mr. Marrazzo has secured more than $1 billion in capital and built an organization of more than 400 colleagues. For two years running, Spark has been named to the top 10 of MIT Technology Review’s “50 Smartest Companies.” It’s also been recognized as one of 2018’s most innovative companies in Biotech by Fast Company. During a career that has spanned the public and private sectors, Mr. Marrazzo has consistently championed the potential benefits of precision medicine and healthcare reform for patients. Prior to Spark, he helped build the first genetic testing benefit management and pharmacogenomics medicines company up to and through the acquisition of a majority of the company's shares by CVS Caremark. Previously, he served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare. Mr. Marrazzo currently serves as a board member of the Biotechnology Innovation Organization (BIO). He received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A./M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.

Sessions
Oct 24 9:15 AM The outlook for gene therapy